Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.

Oncology - 1 Jan 2015

Yoon Kyong-Ah, Woo Sang Myung, Hong Eun Kyung, Jung Mee Kyung, Park Weon Seo, Bae Kieun, Han Sung-Sik, Kim Tae Hyun, Koh Young Hwan, Park Sang-Jae, Lee Woo Jin

Abstract excerpt

OBJECTIVE: Gemcitabine-based chemotherapy is regarded as the standard treatment for biliary tract cancer (BTC). Potential biomarkers for gemcitabine response include the activities of cytidine deaminase (CDA), human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (DCK), and ribonucleotide reductase M1 (RRM1). Here, we investigated whether single nucleotide polymorphisms (SNPs) in their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Lymphatic Metastasis

Share to Neoplasm Recurrence, Local

Share to Ribonucleoside Diphosphate Reductase

Source

Identifiers

PMID: 26418006
DOI: 10.1159/000439222

Genes

BTC
CDA
DCK
RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.PMID 26418006Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Semantic proximity Read ↗

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.Semantic proximity Read ↗

Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.Semantic proximity Read ↗

Gene-Gene Interactions of Gemcitabine Metabolizing-Enzyme Genes hCNT3 and WEE1 for Preventing Severe Gemcitabine-Induced Hematological Toxicity.Semantic proximity Read ↗

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with GemcitabineSemantic proximity Read ↗

Pharmacogenetics in pancreatic cancer.Semantic proximity Read ↗

Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.Semantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.